How to buy Biocept shares

Own Biocept shares in just a few minutes.

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Biocept, Inc is a diagnostics & research business with stocks listed in the US. Biocept shares (BIOC) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$4.34 – a decrease of 3.98% over the previous week. Here's how to invest if you're based in Australia.

How to buy shares in Biocept

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Biocept. Find the share by name or ticker symbol: BIOC. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Biocept reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$4.34, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Biocept, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Biocept. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Biocept share price

Use our graph to track the performance of BIOC stocks over time.

Biocept shares at a glance

Information last updated 2021-06-10.
52-week rangeUS$3.46 - US$11.7
50-day moving average US$4.5846
200-day moving average US$5.2931
Target priceUS$12
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) US$-2.631

Compare share trading platforms to buy stock

Name Product Standard brokerage for US shares Inactivity fee Currency conversion fee Markets
eToro Share Trading (US stocks)
US$0
US$10 per month if there’s been no login for 12 months
0.50%
US shares, ETFs
Zero brokerage share trading on US stocks with trades as low as $50.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
Finder Award
IG Share Trading
US$0
$50 per quarter if you make fewer than three trades in that period
0.70%
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Saxo Capital Markets (Classic account)
US$9.9
No
0.75%
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, ETFs
Acess 19,000+ stocks on 37 exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
CMC Markets Stockbroking
US$0
No
0.60%
ASX shares, Global shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.
loading

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Biocept stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Biocept price performance over time

Historical closes compared with the last close of $4.34

1 week (2021-06-07) -2.69%
1 month (2021-05-14) -2.03%
3 months (2021-03-12) -28.62%
6 months (2020-12-14) -19.03%
1 year (2020-06-12) -21.66%
2 years (2019-06-14) -57.03%
3 years (2018-06-14) 79.34%
5 years (2016-06-14) -32.19%

Biocept financials

Revenue TTM US$43.8 million
Gross profit TTM US$6.1 million
Return on assets TTM -10.33%
Return on equity TTM -27.74%
Profit margin -15.69%
Book value 1.997
Market capitalisation US$60.6 million

TTM: trailing 12 months

Shorting Biocept shares

There are currently 593,482 Biocept shares held short by investors – that's known as Biocept's "short interest". This figure is 23.9% down from 780,300 last month.

There are a few different ways that this level of interest in shorting Biocept shares can be evaluated.

Biocept's "short interest ratio" (SIR)

Biocept's "short interest ratio" (SIR) is the quantity of Biocept shares currently shorted divided by the average quantity of Biocept shares traded daily (recently around 174553.52941176). Biocept's SIR currently stands at 3.4. In other words for every 100,000 Biocept shares traded daily on the market, roughly 3400 shares are currently held short.

However Biocept's short interest can also be evaluated against the total number of Biocept shares, or, against the total number of tradable Biocept shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Biocept's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Biocept shares in existence, roughly 40 shares are currently held short) or 0.0443% of the tradable shares (for every 100,000 tradable Biocept shares, roughly 44 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Biocept.

Find out more about how you can short Biocept stock.

Biocept share dividends

We're not expecting Biocept to pay a dividend over the next 12 months.

Have Biocept's shares ever split?

Biocept's shares were split on a 1:10 basis on 7 September 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Biocept shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Biocept shares which in turn could have impacted Biocept's share price.

Biocept share price volatility

Over the last 12 months, Biocept's shares have ranged in value from as little as US$3.46 up to US$11.7. A popular way to gauge a stock's volatility is its "beta".

BIOC.US volatility(beta: 0.8)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biocept's is 0.7989. This would suggest that Biocept's shares are less volatile than average (for this exchange).

Biocept overview

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor nucleic acid assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. Its Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from circulating tumor DNA; and Target-Selector CTC and molecular platforms provide biomarker detection and monitoring capabilities. In addition, it offers laboratory services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians. Further, it is developing PCR-based assays for detecting the COVID-19 virus. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site
Not sure what platform to go with?
Take this quick quiz to find the right share trading platform